FindTrial
Sign In

Docetaxel/5'DFUR or Docetaxel for advanced or recurrent gastric cancer as 2nd line chemotherapy

Docetaxel/5'DFUR or Docetaxel for advanced or recurrent gastric cancer as 2nd line chemotherapy - 2nd line Docetaxel/5'DFUR for advanced or recurrent gastric cancer

Status
Unknown
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-C000000025
Enrollment
110
Registered
2006-12-31
Start date
2004-01-01
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

gastric cancer

Interventions

Docetaxel 60 mg/m2 iv (tri-weekly) and 5'DFUR 600 mg/body orally (daily), as one course. This is continued until PD or unacceptable toxicity occurs or patients choose to discontinue the treatment. Do

Sponsors

Shinshu Gastroenterological Cancer Study Group
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. histologically proven gastric cancer 2. measurable or evaluable leisions 3. second line chemotherapy 4. adequate interval after first line chemotherapy 5. performance status 0-2 6. adequate organ function 7. estimated survival period: more than 3 months 8. written informed consent

Exclusion criteria

Exclusion criteria: 1. serious complications 2. infection 3. peripheral neuropathy 4. other cancers (except cured cancer) 5. brain metastasis 6. severe pleural effusion or severe ascites 7. allergy to polysorbate 80 8. drug allergy 9. pregnant or lactational

Design outcomes

Primary

MeasureTime frame
response rate, survival, toxicity—

Countries

Japan

Contacts

Public ContactFukuto Maruta

Shinshu University School of Medicine Gastroenterological Surgery

0263-37-2654

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026